Are GLP-1s Treating Type 2 and Type 3 Diabetes?
Are GLP-1s Treating Type 2 and Type 3 Diabetes?
Diabetes mellitus, specifically type 2 diabetes (T2DM), is estimated to impact more than 400 million people globally and is expected to increase to nearly 700 million people by 2045. T2DM is especially prevalent among older adults.
PointClickCare Life Sciences electronic health records data contains more than 3 million records for long-term care residents with T2DM. Our data captures measurements and assessments, including regular blood sugar readings, complete cognitive and physical assessments, and monitoring all medication management to provide a longitudinal patient journey.
To learn how PointClickCare can help you determine the impact GLP-1s are having on type 2 and type 3 diabetes, select the button below.
